Is phosphatemia the best tool to monitor renal tenofovir toxicity? [3]

Journal of Acquired Immune Deficiency Syndromes

Volumn 46, Issue 2, 2007, Pages 256-258

  Essig, Marie ^a   Duval, Xavier ^a   Kaied, Firas Al ^b   Iordache, Laura ^b   Gervais, Anne ^b   Longuet, Pascale ^b   Blanchet, Francoise ^a   Peytavin, Gilles ^a   Leport, Catherine ^b  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; PARATHYROID HORMONE; TENOFOVIR DISOPROXIL;

BONE DENSITY; CALCIUM METABOLISM; CREATININE CLEARANCE; DUAL ENERGY X RAY ABSORPTIOMETRY; FANCONI RENOTUBULAR SYNDROME; GLOMERULUS FILTRATION RATE; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; NEPHROTOXICITY; OSTEOPENIA; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PRIORITY JOURNAL; VITAMIN D METABOLISM;

ADENINE; BIOLOGICAL MARKERS; CREATININE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HUMANS; KIDNEY DISEASES; KIDNEY TUBULES; PHOSPHATES; PHOSPHONIC ACIDS;

EID: 34748895471     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181142f31     Document Type: Letter

References (11)

1. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
2. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS. 2002;16:1257-1263.
3. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis. 2002;40:1331-1333.
4. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. 2003;36:1070-1073.
5. Breton G, Alexandre M, Duval X, et al. Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1. Scand J Infect Dis. 2004;36:527-528.
6. Bijvoet OL. Relation of plasma phosphate concentration to renal tubular reabsorption of phosphate. Clin Sci. 1969;37:23-36.
7. Moreno S, Domingo P, Palacios R, et al. Renal safety of tenofovir disoproxil fumarate in HIV-1 treatment-experienced patients with adverse events related to prior NRTI use: data from a prospective, observational, multicenter study. J Acquir Immune Defic Syndr. 2006;42:385-387.
8. Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant. 2005;20:743-746.
9. Badiou S, De Boever CM, Terrier N, et al. Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults? J Infect. 2006;52:335-338.
10. Madeddu G, Spanu A, Solinas P, et al. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med. 2004;48:39-48.
11. Cozzolino M, Vidal M, Arcidiacono MV, et al. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS. 2003;17:513-520.